Brief: Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
09/03/2026 21:34
March 9 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES POSITIVE WEEK 36 INTERIM ANALYSIS RESULTS FOR PRIMARY AND ALL SECONDARY ENDPOINTS IN THE RAINIER PHASE 3 TRIAL OF POVETACICEPT IN ADULTS WITH IGA NEPHROPATHY VERTEX PHARMACEUTICALS INC - TO COMPLETE BLA FOR POVETACICEPT BY END OF MARCH FOR POTENTIAL U.S. ACCELERATED APPROVAL VERTEX PHARMACEUTICALS: POVETACICEPT WAS GENERALLY SAFE AND WELL TOLERATED Source text: ID:nBw2NCH39a Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria